Herlander Marques
Hospital Braga(PT)Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas(BR)Unidade Hospitalar de Bragança(PT)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Lymphoma Diagnosis and Treatment, Protein Degradation and Inhibitors, Chronic Lymphocytic Leukemia Research, MicroRNA in disease regulation
Most-Cited Works
- → Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study(2018)135 cited
- → Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma – MCT1 as potential target in diffuse large B cell lymphoma(2019)66 cited
- → Significance of glycolytic metabolism-related protein expression in colorectal cancer, lymph node and hepatic metastasis(2016)65 cited
- → Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients(2015)44 cited
- → FcγRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients(2008)42 cited
- →